Pulmonology Medical News about non-small-cell lung cancer;brain metastasis;Bevacizumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases
Journal of Clinical Oncology, 09/11/09

Socinski MA et al. – Addition of bevacizumab to various chemotherapy agents or erlotinib in patients with NSCLC and treated brain metastases seems to be safe and is associated with a low incidence of CNS hemorrhage.

Methods

This open-label multicenter trial for first- and second-line treatment of nonsquamous NSCLC enrolled patients with treated brain metastases
First-line patients received bevacizumab (15 mg/kg) every 3 weeks with platinum-based doublet therapy or erlotinib (at physician's decision), and second-line patients received bevacizumab with single-agent chemotherapy or erlotinib, until disease progression or death

Results

Of the 115 enrolled patients, 66 of 76 first-line patients received carboplatin-based chemotherapy; 22 of 39 second-line patients received pemetrexed, and nine of 39 received erlotinib
Among 106 safety-evaluable patients, median on-study duration was 6.3 mos(range, 0-22 mos), with a median of 5 bevacizumab cycles (range, 1-17), and no reported episodes of grade 2 CNS hemorrhage
Of the bevacizumab-targeted adverse events reported, 2were grade 5
Both were pulmonary hemorrhages, one occurring during treatment and the other occurring 6 weeks after the data cut; there was also one grade 4, nonpulmonary/non-CNS hemorrhage
26 patients (24.5%) discontinued study treatment as a result of an adverse event, and 37 (34.9%) discontinued because of disease progression

<< Previous
Defining chronic obstructive pulmonary disease in older persons

Next >>
Randomized, placebo-controlled, phase II study of sequential...